Provided by Tiger Fintech (Singapore) Pte. Ltd.

MannKind

4.99
+0.01000.20%
Post-market: 5.040.0500+1.00%18:40 EDT
Volume:2.82M
Turnover:13.88M
Market Cap:1.51B
PE:49.90
High:5.04
Open:4.91
Low:4.77
Close:4.98
Loading ...

Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.
·
23 Dec 2024

MannKind Shares Rise After Wells Fargo Begins Coverage

MT Newswires Live
·
21 Dec 2024

Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target

MT Newswires Live
·
20 Dec 2024

MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years

Simply Wall St.
·
20 Dec 2024

MannKind Shares Rise After Upgrade From RBC

MT Newswires Live
·
20 Dec 2024

MannKind Raised to Outperform From Sector Perform by RBC Capital

Dow Jones
·
20 Dec 2024

RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7

MT Newswires Live
·
19 Dec 2024

MannKind upgraded to Outperform from Sector Perform at RBC Capital

TIPRANKS
·
19 Dec 2024

U.S. RESEARCH ROUNDUP- Amazon, Mastercard, Tesla

Reuters
·
19 Dec 2024

MannKind Corp : RBC Raises to Outperform From Sector Perform; Raises Target Price to $10 From $7

THOMSON REUTERS
·
19 Dec 2024

MannKind Launches Exchange of Convertible Notes With Cash, Common Stock

MT Newswires Live
·
18 Dec 2024

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

THOMSON REUTERS
·
18 Dec 2024

MannKind Corp: Debt Reduced by $194 Mln

THOMSON REUTERS
·
18 Dec 2024

Leerink Partners Keeps Their Buy Rating on MannKind (MNKD)

TIPRANKS
·
18 Dec 2024

MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint

MT Newswires Live
·
16 Dec 2024